Efficacy and Safety of a Single Dose of Emodepside Compared to a Single Dose of Albendazole in Adolescents and Adults Infected With Trichuris Incognita

Exclusion Criteria

• •Presence or signs of major systemic illnesses, e.g. body temperature ≥ 38 °C, severe anemia (Hb below 80g/l) upon initial clinical assessment etc.
• •History of severe acute or unmanaged severe chronic disease (i.e., condition is not as therapeutically controlled as necessary).
• •Positive malaria rapid diagnostic test (RDT) and temperature ≥ 38 °C.
• •Abnormal liver and renal function assessed by biochemical blood-based analyses
• •Recent use of anthelmintic drugs (in the 4 weeks before treatment).
• •Known allergy to study medications and formulations (i.e., albendazole and emodepside).
• •Prescribed or taking medication with known contraindication to or interaction with study drugs.
• •Participating in other clinical trials during the study period.
• •Pregnancy or breastfeeding